smb café 12 sep '13 - tobbb - sijme zeilemaker
DESCRIPTION
Presentation by Sijme Zeilemaker of ToBBB for the Science meets Business café of 12 sep 2013. This event was held in the BioPartner Accelerator building in Leiden.TRANSCRIPT
![Page 1: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/1.jpg)
Safely Enhancing Drug Delivery to the CNS
An Innovative Platform Technology
Sijme Zeilemaker, MScBusiness Development Associateto-BBB
Science meets BusinessSeptember 2013
![Page 2: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/2.jpg)
Background
2005 – 2011 Biomedical Sciences at Leiden University
2008: LACDR internship
Master Biomedical Sciences – Management
Science Based Business
2010: Business Internship
![Page 3: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/3.jpg)
A start-up company in neuroscience…
Blood-Brain Barrier
600 kilometer
Every neuron has its own capillary
![Page 4: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/4.jpg)
• G-Technology®: safe brain delivery technology• Glutathione: safe brain targeting mechanism • PEG-liposomes: well-established delivery technology• Strong patent protection on any drug combination
to-BBB’s brain drug delivery platform
![Page 5: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/5.jpg)
G-Technology: mechanistic validation in vitro
![Page 6: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/6.jpg)
5 times more in brain improved anti-cancer effect
G-Technology: mechanistic validation in vivo
Doxil/Caelyx: PEG liposomal doxorubicin2B3-101: Glutathione-PEG liposomal doxorubicin
![Page 7: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/7.jpg)
2B3-101: confirming the safe brain delivery platform
Lead product 2B3-101 treating patients with brain cancer•Therapeutic dosages reached with a predictable safety profile
•Favorable long circulation plasma half-life of 64 hours
•Early signs of clinical efficacy with partial responses and stable disease
•Results to be presented at European Cancer Congress, Amsterdam
![Page 8: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/8.jpg)
2-fold business model: internal development
![Page 9: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/9.jpg)
Enhanced uptake across CNS•Safe, endogenous mechanism
Increased half life•Reduce dosing frequency
Liposomal shielding•Reduce side effects
Strong IP protection•Life Cycle Management
2-fold business model: pharma/biotech partnering
this could be your compound!
![Page 10: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/10.jpg)
Business Development: all about partnering
Pharma*:
Mid-size pharma / biotech*:
Grants:
*examples
![Page 11: SmB café 12 Sep '13 - ToBBB - Sijme Zeilemaker](https://reader035.vdocuments.net/reader035/viewer/2022062319/557a98e8d8b42aa0568b49b4/html5/thumbnails/11.jpg)
Business Development: getting done more… with less
Pharma*:
Mid-size pharma / biotech*:
Grants:
*examples
build a leading company in brain drug development
build a leading company in brain drug development